Cynomolgus ACVR2B recombinant protein

Cynomolgus ACVR2B recombinant protein

• DataSheet
• Material Safety Data Sheets (MSDS)

ACVR2A and ACVR2B are two activin type II receptors. ACVR2B is integral to the activin and myostatin signaling pathway. Ligands such as activin and myostatin bind to ACVR2A and ACVR2B. Myostatin, a negative regulator of skeletal muscle growth, is regarded as a potential therapeutic target and binds to ACVR2B effectively, and to a lesser extent, to ACVR2A. The structure of human ACVR2B kinase domain in complex with adenine establishes the conserved bilobal architecture consistent with all other catalytic kinase domains. Haplotype structure at the ACVR2B and follistatin loci may contribute to interindividual variation in skeletal muscle mass and strength. Defects in ACVR2B are a cause of left-right axis malformations.

Serine/threonine-protein kinase receptor

MGC118477; ACVR2B; ACTRIIB; HTX4; MGC116908; ACTR-IIB

G7MJ10

EGK_11790

Human Cells

A DNA sequence encoding the cynomolgus ACVR2B (EHH16502.1) (Ser28-Thr143) was expressed with six amino acids (LEVLFQ) at the C-terminus.

Cynomolgus

The recombinant cynomolgus ACVR2B is a disulfide-linked homodimer. The reduced monomer comprises 123 amino acids and has a calculated molecular mass of 14.1 KDa.The apparent molecular mass of the protein is approximately 34 KDa in SDS-PAGE.

> 95 % as determined by SDS-PAGE

Measured by its ability to neutralize Activin-mediated inhibition on MPC11 cell proliferation.
The ED₅₀ for this effect is typically 0.2-0.6 µg/mL in the presence of 10 ng/mL recombinant Activin A.